Exec appointment
The filing discloses the appointment of Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Officer) of Retension Pharmaceuticals, effective November 2, 2026. The principal disclosed action is a person taking a role—a key executive position responsible for accounting and financial reporting. While the filing also includes compensatory details (base salary, bonus, sign-on bonus, and stock options), the core event is the appointment itself, making this an exec_appointment rather than exec_compensation.
View raw filing on EDGAR →